Literature DB >> 20972894

MR Imaging of activated hepatic stellate cells in liver injured by CCl4 of rats with integrin-targeted ultrasmall superparamagnetic iron oxide.

Qing-Bing Wang1, Yu Han, Ting-Ting Jiang, Wei-Min Chai, Ke-Min Chen, Bing-Ya Liu, Li-Fu Wang, Chunfu Zhang, Deng-Bin Wang.   

Abstract

OBJECTIVE: To demonstrate the feasibility of the ultrasmall superparamagnetic iron oxide (USPIO) modified by cyclo (Arg-Gly-Asp-Try-Cys) peptide (c(RGDyC)-USPIO) for targeting hepatic stellate cells (HSCs).
MATERIALS AND METHODS: A c(RGDyC)-USPIO probe was prepared by conjugating c(RGDyC) with USPIO through a thiol-maleinide interaction. The specificity of c(RGDyC)-USPIO for HSCs was investigated in vitro. In vivo, normal and fibrosis rats were treated with either c(RGDyC)-USPIO or USPIO, and magnetic resonance imaging (MRI) of the rats performed after administration of the probes for 4 h. The T2 relaxation times changes before and after probe injection were analyzed and the locations of probes in normal or injured mice were identified histologically.
RESULTS: The hydrodynamic size of c(RGDyC)-USPIO was 13 ± 3 nm. HSCs took up more specific probes than plain ones. The reduction of T2 relaxation times in fibrosis rat by c(RGDyC)-USPIO was much greater than that by USPIO (P < 0.05). Prussian blue staining and transmission electron microscopy of the injured rat liver treated with c(RGDyC) demonstrated that c(RGDyC)-USPIO were specifically engulfed by the activated HSCs.
CONCLUSION: In vivo cellular targeted imaging of activated HSCs in liver fibrosis using c(RGDyC)-USPIO targeting α(v)β(3) integrins was feasible using a clinical 1.5-Tesla MR system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20972894     DOI: 10.1007/s00330-010-1988-z

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  35 in total

1.  Interaction of targeted liposomes with primary cultured hepatic stellate cells: Involvement of multiple receptor systems.

Authors:  Joanna E Adrian; Klaas Poelstra; Gerrit L Scherphof; Grietje Molema; Dirk K F Meijer; Catharina Reker-Smit; Henriëtte W M Morselt; Jan A A M Kamps
Journal:  J Hepatol       Date:  2005-10-19       Impact factor: 25.083

Review 2.  Liver cirrhosis and hepatic stellate cells.

Authors:  Daniel Ferracioli Brandão; Leandra Naira Zambelli Ramalho; Fernando Silva Ramalho; Sérgio Zucoloto; Ana de Lourdes Candolo Martinelli; Orlando de Castro e Silva
Journal:  Acta Cir Bras       Date:  2006       Impact factor: 1.388

3.  Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor.

Authors:  L Beljaars; G Molema; D Schuppan; A Geerts; P J De Bleser; B Weert; D K Meijer; K Poelstra
Journal:  J Biol Chem       Date:  2000-04-28       Impact factor: 5.157

4.  Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging.

Authors:  Diego A Aguirre; Cynthia A Behling; Elliot Alpert; Tarek I Hassanein; Claude B Sirlin
Journal:  Radiology       Date:  2006-05       Impact factor: 11.105

Review 5.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

6.  Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner.

Authors:  Chunfu Zhang; Manfred Jugold; Eva C Woenne; Twan Lammers; Bernd Morgenstern; Margareta M Mueller; Hanswalter Zentgraf; Michael Bock; Michael Eisenhut; Wolfhard Semmler; Fabian Kiessling
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

7.  Arg-gly-asp-mannose-6-phosphate inhibits activation and proliferation of hepatic stellate cells in vitro.

Authors:  Lian-Sheng Wang; Ying-Wei Chen; Ding-Guo Li; Han-Ming Lu
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

8.  Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model.

Authors:  Anne H Schmieder; Shelton D Caruthers; Huiying Zhang; Todd A Williams; J David Robertson; Samuel A Wickline; Gregory M Lanza
Journal:  FASEB J       Date:  2008-08-12       Impact factor: 5.191

Review 9.  Advances in antifibrotic therapy.

Authors:  Zahra Ghiassi-Nejad; Scott L Friedman
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-12       Impact factor: 3.869

10.  Parametric exploration of the liver by magnetic resonance methods.

Authors:  Paul E Sijens
Journal:  Eur Radiol       Date:  2009-06-06       Impact factor: 5.315

View more
  8 in total

Review 1.  Advances in functional and molecular MRI technologies in chronic liver diseases.

Authors:  Iris Y Zhou; Onofrio A Catalano; Peter Caravan
Journal:  J Hepatol       Date:  2020-06-22       Impact factor: 25.083

Review 2.  Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies.

Authors:  Don C Rockey
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-07       Impact factor: 11.382

3.  Molecular MRI of liver fibrosis by a peptide-targeted contrast agent in an experimental mouse model.

Authors:  April M Chow; Mingqian Tan; Darwin S Gao; Shu Juan Fan; Jerry S Cheung; Kwan Man; Zheng-Rong Lu; Ed X Wu
Journal:  Invest Radiol       Date:  2013-01       Impact factor: 6.016

Review 4.  Recent advances in molecular magnetic resonance imaging of liver fibrosis.

Authors:  Zhiming Li; Jihong Sun; Xiaoming Yang
Journal:  Biomed Res Int       Date:  2015-03-22       Impact factor: 3.411

5.  Molecular magnetic resonance imaging of activated hepatic stellate cells with ultrasmall superparamagnetic iron oxide targeting integrin αvβ₃ for staging liver fibrosis in rat model.

Authors:  Caiyuan Zhang; Huanhuan Liu; Yanfen Cui; Xiaoming Li; Zhongyang Zhang; Yong Zhang; Dengbin Wang
Journal:  Int J Nanomedicine       Date:  2016-03-18

6.  Enhanced US/CT/MR imaging of integrin αvβ3 for liver fibrosis staging in rat.

Authors:  Xueyao Tang; Xuan Li; Mingxing Li; Xiaoling Zhong; Wenguang Fu; Meng Ao; Jiqing Xuan
Journal:  Front Chem       Date:  2022-10-03       Impact factor: 5.545

7.  Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging.

Authors:  Dan Li; Li He; Huizhuang Guo; Hanwei Chen; Hong Shan
Journal:  EJNMMI Res       Date:  2015-12-09       Impact factor: 3.138

8.  Surface engineered antifouling optomagnetic SPIONs for bimodal targeted imaging of pancreatic cancer cells.

Authors:  Xiaohui Wang; Xiaohong Xing; Bingbo Zhang; Fengjun Liu; Yingsheng Cheng; Donglu Shi
Journal:  Int J Nanomedicine       Date:  2014-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.